Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers

详细信息    查看全文

• 作者：Claudia Marchetti (1)
  Francesca De Felice (2)
  Innocenza Palaia (1)
  Giorgia Perniola (1)
  Angela Musella (1)
  Daniela Musio (2)
  Ludovico Muzii (1)
  Vincenzo Tombolini (2)
  Pierluigi Benedetti Panici (1)
  
  1. Department of Gynecological and Obstetrical Sciences and Urological Sciences ; University of Rome 2鈥淪apienza鈥? Viale del Policlinico ; 155 ; 00161 ; Rome ; Italy
  2. Department of Radiotherapy ; Policlinico Umberto I 鈥淪apienza鈥?University of Rome ; Viale Regina Elena 326 ; 00161 ; Rome ; Italy
  
• 关键词：Risk ; reducing salpingo ; oophorectomy ; Prophylactic ; BRCA ; Ovarian cancer ; Cause ; Meta ; analysis
• 刊名：BMC Women's Health
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：716 KB
• 参考文献：1. Bougie, O, Weberpals, JI (2011) Clinical considerations of BRCA1- and BRCA2- mutation carriers: a review. Int J Surg Oncol 2011: pp. 374012
  2. King, MC, Marks, JH, Mandell, JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302: pp. 643-646 CrossRef
  3. Surveillance, Epidemiology, and End Results (SEER) Program. Research Data (1973-2009), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch. [released April 2012 based on November 2011 submission]. Available at: www.seer.cancer.gov.
  4. National Comprehensive Cancer Network (NCCN): Genetic High-Risk familial Assessment: Breast and Ovarian. 2013; 4:2013. [Available from: http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf]
  5. Finch, A, Beiner, M, Lubinski, J, Lynch, HT, Moller, P, Rosen, B, Murphy, J, Ghadirian, P, Friedman, E, Foulkes, WD, Kim-Sing, C, Wagner, T, Tung, N, Couch, F, Stoppa-Lyonnet, D, Ainsworth, P, Daly, M, Pasini, B, Gershoni-Baruch, R, Eng, C, Olopade, OI, McLennan, J, Karlan, B, Weitzel, J, Sun, P, Narod, SA (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296: pp. 185-192 CrossRef
  6. Finch, AP, Lubinski, J, M酶ller, P, Singer, CF, Karlan, B, Senter, L, Rosen, B, Maehle, L, Ghadirian, P, Cybulski, C, Huzarski, T, Eisen, A, Foulkes, WD, Kim-Sing, C, Ainsworth, P, Tung, N, Lynch, HT, Neuhausen, S, Metcalfe, KA, Thompson, I, Murphy, J, Sun, P, Narod, SA, Cybulski, C, Huzarski, T, Eisen, A, Foulkes, WD, Kim-Sing, C, Ainsworth, P, Tung, N (2014) Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32: pp. 1547-1553 CrossRef
  7. Tierney, JF, Stewart, LA, Ghersi, D, Burdett, S, Sydes, MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: pp. 16 CrossRef
  8. Higgins, JPT, Thompson, SG, Deeks, JJ, Altman, DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: pp. 557-560 CrossRef
  9. Egger, M, Davey, SG, Schneider, M, Minder, C (1997) Bias in meta-analysis detected by a simple, graphical test. BJM 315: pp. 629-634 CrossRef
  10. Begg, CB, Mazumdar, M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: pp. 1008-1101 CrossRef
  11. Rutter, JL, Wacholder, S, Chetrit, A, Lubin, F, Menczer, J, Ebbers, S, Tucker, MA, Struewing, JP, Hartge, P (2003) Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst 95: pp. 1072-1078 CrossRef
  12. Rebbeck, TR, Lynch, HT, Neuhausen, SL, Narod, SA, Veer, L, Garber, JE, Evans, G, Isaacs, C, Daly, MB, Matloff, E, Olopade, OI, Weber, BL (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346: pp. 1616-1622 CrossRef
  13. Domchek, SM, Friebel, TM, Singer, CF, Evans, DG, Lynch, HT, Isaacs, C, Garber, JE, Neuhausen, SL, Matloff, E, Eeles, R, Pichert, G, Van t'veer, L, Tung, N, Weitzel, JN, Couch, FJ, Rubinstein, WS, Ganz, PA, Daly, MB, Olopade, OI, Tomlinson, G, Schildkraut, J, Blum, JL, Rebbeck, TR (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304: pp. 967-975 CrossRef
  14. Kauff, ND, Domchek, SM, Friebel, TM, Robson, ME, Lee, J, Garber, JE, Isaacs, C, Evans, DG, Lynch, H, Eeles, RA, Neuhausen, SL, Daly, MB, Matloff, E, Blum, JL, Sabbatini, P, Barakat, RR, Hudis, C, Norton, L, Offit, K, Rebbeck, TR (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26: pp. 1331-1337 CrossRef
  15. Rebbeck, TR, Kauff, ND, Domchek, SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101: pp. 80-87 CrossRef
  16. Satagopan, JM, Boyd, J, Kauff, ND, Robson, M, Scheuer, L, Narod, S, Offit, K (2002) Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 8: pp. 3776-3781
  17. Rocca, WA, Grossardt, BR, Andrade, M, Malkasian, GD, Melton, LJ (2006) Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 7: pp. 821-828 CrossRef
  18. Metcalfe, KA, Ghadirian, P, Rosen, B, Foulkes, W, Kim-Sing, C, Eisen, A, Ainsworth, P, Horsman, D, Maugard, C, Provencher, D, Robideaux, A, Gilchrist, D, Chudley, A, Lemire, EG, Armel, S, Finch, A, Sun, P, Narod, SA (2007) Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. Open Med 2: pp. 92-98
  19. Metcalfe, KA, Birenbaum-Carmeli, D, Lubinski, J, Gronwald, J, Lynch, H, Moller, P, Ghadirian, P, Foulkes, WD, Klijn, J, Friedman, E, Kim-Sing, C, Ainsworth, P, Rosen, B, Domchek, S, Wagner, T, Tung, N, Manoukian, S, Couch, F, Sun, P, Narod, SA (2008) International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122: pp. 2017-2022 CrossRef
  20. Madalinska, JB, Hollenstein, J, Bleiker, E, Beurden, M, Valdimarsdottir, HB, Massuger, LF, Gaarenstroom, KN, Mourits, MJ, Verheijen, RH, Dorst, EB, Putten, H, Velden, K, Boonstra, H, Aaronson, NK (2005) Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23: pp. 6890-6898 CrossRef
  21. Finch, A, Evans, G, Narod, SA (2012) BRCA carriers, prophylactic salpingooophorectomy and menopause: clinical management considerations and recommendations. Womens Health 5: pp. 543-555
  22. Marchetti, C, Iadarola, R, Palaia, I, Donato, V, Perniola, G, Muzii, L, Panici, PB (2014) Hormone therapy in oophorectomized BRCA1/2 mutation carriers. Menopause 21: pp. 763-768 CrossRef
  
• 刊物主题：Gynecology; Maternal and Child Health; Reproductive Medicine;
• 出版者：BioMed Central
• ISSN：1472-6874

文摘

Background Women with BRCA1 and BRCA2 mutation carriers are at substantially elevated risk of developing ovarian cancer. The aim of the meta-analysis is to clarify the role of risk-reducing salpingo-oophorectomy (RRSO) to reduce ovarian cancer risk and mortality in women with BRCA 1 and BRCA 2 mutation carriers. Methods Pubmed, Medline and Scopus were searched to select English-language articles. Two investigators independently extracted characteristics and results of selected studies. Articles were included only if prospective and if absolute numbers of ovarian cancer and death events were available or derivable from the test. Pooled hazard ratio (HR) with 95% confidence interval (CI) was calculated using fixed effects model. Results Meta-analysis of 3 prospective studies demonstrated a significant risk reduction of ovarian cancer with RRSO in BRCA 1 and BRCA 2 mutation carriers, as well as benefit in all-causes mortality incidence. Conclusions It may be justified to recommend RRSO to reduce ovarian cancer risk and all-causes mortality in women with a mutation in BRCA 1 and BRCA 2.